Anti-inflammatory cytokines and risk of type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 15, Issue S3, 2013, Pages 39-50

  Herder, C ^a   Carstensen, M ^a   Ouwens, D M ^a,b  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anti inflammatory; Cytokines; Epidemiological; Inflammation; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ANTIHYPERTENSIVE AGENT; CYTOKINE; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN A1C; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; SECRETED FRIZZLED RELATED PROTEIN 5; TRANSFORMING GROWTH FACTOR BETA1;

HUMAN; METABOLIC REGULATION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; UPREGULATION;

ANTI-INFLAMMATORY; CYTOKINES; EPIDEMIOLOGICAL; INFLAMMATION; TYPE 2 DIABETES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; RISK FACTORS;

EID: 84883436075     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12155     Document Type: Review

References (101)

1. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
2. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-445.
3. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-374.
4. Kolb H, Mandrup-Poulsen T. The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia 2010; 53: 10-20.
5. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171-186.
6. Häfner S, Emeny RT, Lacruz ME et al. Association between social isolation and inflammatory markers in depressed and non-depressed individuals: results from the MONICA/KORA study. Brain Behav Immun 2011; 25: 1701-1707.
7. Rajagopalan S, Brook RD. Air pollution and type 2 diabetes: mechanistic insights. Diabetes 2012; 61: 3037-3045.
8. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ 2011; 342: d548.
9. Preshaw PM, Alba AL, Herrera D et al. Periodontitis and diabetes: a two-way relationship. Diabetologia 2012; 55: 21-31.
10. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48: 1038-1050.
11. Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia 2008; 51: 926-940.
12. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 2010; 21: 261-267.
13. Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 2012; 8: 709-716.
14. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-89.
15. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
16. Cavelti-Weder C, Babians-Brunner A, Keller C et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012; 35: 1654-1662.
17. Goldfine AB, Fonseca V, Jablonski KA et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152: 346-357.
18. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005; 7: 675-691.
19. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
20. Thorand B, Kolb H, Baumert J et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes 2005; 54: 2932-2938.
21. Herder C, Baumert J, Thorand B et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 2006; 49: 921-929.
22. Germain RN. Maintaining system homeostasis: the third law of Newtonian immunology. Nat Immunol 2012; 13: 902-906.
23. Murray PJ, Smale ST. Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. Nat Immunol 2012; 13: 916-924.
24. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55: 2319-2326.
25. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-1033.
26. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-89.
27. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302: 179-188.
28. Waki H, Yamauchi T, Kamon J et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-40363.
29. Kizer JR, Arnold AM, Benkeser D et al. Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care 2012; 35: 415-423.
30. Hivert MF, Sullivan LM, Shrader P et al. Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. Diabetologia 2011; 54: 1019-1024.
31. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, Koenig W. Associations between leptin and the leptin/adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984-2002. Diabet Med 2010; 27: 1004-1011.
32. Tabak AG, Carstensen M, Witte DR et al. Adiponectin trajectories before type 2 diabetes diagnosis. Whitehall II Study. Diabetes Care 2012; 35: 2540-2547.
33. Rathmann W, Herder C. Adiponectin and cardiovascular mortality: evidence for "reverse epidemiology". Horm Metab Res 2007; 39: 1-2.
34. Sattar N, Nelson SM. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab 2008; 93: 3299-3301.
35. Sattar N. Adiponectin and raised mortality in type 1 diabetes: any credible explanatory mechanisms? J Intern Med 2011; 270: 339-342.
36. Cook JR, Semple RK. Hypoadiponectinemia - cause or consequence of human "insulin resistance"? J Clin Endocrinol Metab 2010; 95: 1544-1554.
37. Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008; 6: 87-102.
38. Sierksma A, Patel H, Ouchi N et al. Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care 2004; 27: 184-189.
39. Kempf K, Herder C, Erlund I et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 2010; 91: 950-957.
40. Gao H, Fall T, van Dam RM et al. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian Randomization study. Diabetes 2013; 62: 1338-1344.
41. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-3732.
42. Aksentijevich I, Masters SL, Ferguson PJ et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-2437.
43. Reddy S, Jia S, Geoffrey R et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360: 2438-2444.
44. Lagathu C, Yvan-Charvet L, Bastard JP et al. Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes. Diabetologia 2006; 49: 2162-2173.
45. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1β-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148: 241-245.
46. Nov O, Kohl A, Lewis EC et al. Interleukin-1β may mediate insulin resistance in liver-derived cells in response to adipocyte inflammation. Endocrinology 2010; 151: 4247-4256.
47. Herder C, Brunner EJ, Rathmann W et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32: 421-423.
48. Carstensen M, Herder C, Kivimäki M et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010; 59: 1222-1227.
49. Luotola K, Pietilä A, Zeller T et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. J Intern Med 2011; 269: 322-332.
50. Salomaa V, Havulinna A, Saarela O et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One 2010; 5: e10100.
51. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550.
52. Larsen CM, Faulenbach M, Vaag A et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-1668.
53. Ridker PM, Howard CP, Walter V et al. Effects of interleukin-1β inhibition with canakinumab on haemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012; 126: 2739-2748.
54. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162: 597-605.
55. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
56. Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012; 13: 925-931.
57. Herder C, Zierer A, Koenig W, Roden M, Meisinger C, Thorand B. Transforming growth factor-β1 and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-2002. Diabetes Care 2009; 32: 1921-1923.
58. Carstensen M, Herder C, Brunner EJ et al. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol 2010; 162: 913-917.
59. Kempf T, Guba-Quint A, Torgerson J et al. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur J Endocrinol 2012; 167: 671-678.
60. Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-β and interleukin-10. Immunity 2008; 28: 468-476.
61. Wan YY, Flavell RA. 'Yin-Yang' functions of transforming growth factor-β and T regulatory cells in immune regulation. Immunol Rev 2007; 220: 199-213.
62. Thorand B, Baumert J, Koenig W et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007; 30: 854-860.
63. Miljkovic D, Cvetkovic I, Momcilovic M, Maksimovic-Ivanic D, Stosic-Grujicic S, Trajkovic V. Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse β cells. Cell Mol Life Sci 2005; 62: 2658-2668.
64. Smart NG, Apelqvist AA, Gu X et al. Conditional expression of Smad7 in pancreatic β cells disrupts TGF-β signaling and induces reversible diabetes mellitus. PLoS Biol 2006; 4: e39.
65. Brown ML, Schneyer AL. Emerging roles for the TGFβ family in pancreatic β-cell homeostasis. Trends Endocrinol Metab 2010; 21: 441-448.
66. Bootcov MR, Bauskin AR, Valenzuela SM et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci USA 1997; 94: 11514-11519.
67. Ding Q, Mracek T, Gonzalez-Muniesa P et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 2009; 150: 1688-1696.
68. Shimano M, Ouchi N, Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation 2012; 126: e327-332.
69. Vila G, Riedl M, Anderwald C et al. The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem 2011; 57: 309-316.
70. Ho JE, Mahajan A, Chen MH et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem 2012; 58: 1582-1591.
71. Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 2012; 9: 337-345.
72. Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 9: 683-765.
73. Hong EG, Ko HJ, Cho YR et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 2009; 58: 2525-2535.
74. Van Exel E, Gussekloo J, de Craen AJ et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002; 51: 1088-1092.
75. Blüher M, Fasshauer M, Tönjes A, Kratzsch J, Schön MR, Paschke R. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 2005; 113: 534-537.
76. Pham MN, Hawa MI, Pfleger C et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia 2011; 54: 1630-1638.
77. Welsh P, Murray HM, Ford I et al. Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol 2011; 31: 2338-2344.
78. Yang RZ, Lee MJ, Hu H et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-1261.
79. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 20: 143-148.
80. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011; 408: 339-343.
81. Zhong X, Li X, Liu F, Tan H, Shang D. Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway. Biochem Biophys Res Commun 2012; 425: 401-406.
82. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012; 686: 116-123.
83. De Souza Batista CM, Yang RZ, Lee MJ et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661.
84. Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 257-263.
85. Saremi A, Asghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci 2010; 28: 993-998.
86. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010; 88: 29-33.
87. Moreno-Navarrete JM, Catalán V, Ortega F et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010; 7: 27.
88. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010; 59: 3023-3031.
89. Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani M. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial. Regul Pept 2013; 182: 1-6.
90. Greulich S, Chen WJY, Maxhera B et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One 2013; 8: e59697.
91. Tan BK, Pua S, Syed F, Lewandowski KC, O'Hare JP, Randeva HS. Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabet Med 2008; 25: 1254-1255.
92. Koza RA, Nikonova L, Hogan J et al. Changes in gene expression foreshadow diet-induced obesity in genetically identical mice. PLoS Genet 2006; 2: 769-780.
93. Ouchi N, Higuchi A, Ohashi K et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010; 329: 454-457.
94. Hu W, Li L, Yang M et al. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab 2013; 98: 290-298.
95. Hu Z, Deng H, Qu H. Plasma Sfrp5 levels are decreased in Chinese subjects with obesity and type 2 diabetes and negatively correlated with parameters of insulin resistance. Diabetes Res Clin Pract 2013; 99: 391-395.
96. Carstensen M, Herder C, Kempf K et al. Sfrp5 correlates with insulin resistance and oxidative stress. Eur J Clin Invest 2013; 43: 350-357.
97. Flehmig G, Fasshauer M, Klöting N, Schön MR, Stumvoll M, Blüher M. Sfrp5 serum concentration is associated with measures of glucose homeostasis and insulin sensitivity in human obesity (Abstract). Diabetologie Stoffwechs 2012; 7(S1): S35.
98. Schulte DM, Müller N, Neumann K et al. Pro-inflammatory wnt5a and anti-inflammatory sFRP5 are differentially regulated by nutritional factors in obese human subjects. PLoS One 2012; 7: e32437.
99. Ehrlund A, Mejhert N, Lorente-Cebrián S et al. Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. J Clin Endocrinol Metab 2013; 98: E503-508.
100. Kolb H, Eizirik DL. Resistance to type 2 diabetes mellitus: a matter of hormesis? Nat Rev Endocrinol 2011; 8: 183-192.
101. Miller AM, Asquith DL, Hueber AJ et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2010; 107: 650-658.